You are here

TOP 6 Flash Poster Presentations

Vertical Tabs

Vertical Tabs

TOP 6 Webinar Recordings

TOP 6 Flash Poster Presentations

Webinar Recordings
TOP 6 Flash Poster Presentations Overview

Since 2018, CTMSS has provided a speaking platform for the Top 4 Poster Abstracts at the Annual Meeting. We are thrilled to be able to continue to share our top research and findings.

The Abstract Review Committee decided to include an additional two abstracts this year to be presented since the 2020 Annual Meeting in Chicago was regrettably canceled. These abstracts were originally scheduled as general presentations for the conference and as such, were not eligible for being selected to present during this session. Thus, this year there was a total of 6 top abstracts presented. 

Moderated by Andy Kozel, MD, CTMSS Research Chair

Dr. Kozel is the Director of the TMS Clinic and Staff Psychiatrist in Mental Health and Behavioral Sciences (MH&BS) at the James A. Haley Veteran's Hospital; as well as Professor, Department of Psychiatry and Behavioral Sciences, University of South Florida. Dr. Kozel's work with neuromodulation techniques like TMS has included research, clinical care, teaching, and dissemination for over 20 years. His research uses brain imaging and brain stimulation to better understand and treat neuropsychiatric disorders with the focus of improving the lives of patients with these disorders.

Anhedonia in Major Depressive Disorder: Can it be the Chicken and the Egg for Transcranial Magnetic Stimulation?

Anhedonia is a severely debilitating hallmark feature of Major Depressive Disorder (MDD) and a symptom which is often difficult to treat. Snaith-Hamilton Pleasure Scale (SHAPS), a validated 14-question self-assessment for anhedonia, was collected in a naturalistic setting before and after TMS for treatment-resistant MDD. TMS resulted in a significant improvement in hedonic drive from pre to post TMS overall. Patients whose MDD met response criteria had a significantly greater degree of improvement in hedonic drive. However, baseline anhedonia severity was not a predictor of TMS clinical response.

Presented by Andrew M. Fukuda, MD, PhD

Dr. Fukuda is a 3rd year General Psychiatry Resident at Brown University and is also part of the NIMH R25-funded research track. He earned his MD and Ph.D. from Loma Linda University in California through the Medical Scientist Training Program. He has been engaged in TMS research under the mentorship of Dr. Linda Carpenter since starting residency.

Does it Matter if Depressed Patients get TMS Sessions Less Often than 5 Times per Week? A Treatment Schedule Density Analysis

TMS therapy for Major Depressive Disorder (MDD) was administered on a strictly-enforced schedule of 5 sessions per week for the first 4-6 weeks. In real-life clinical practice, circumstances that prevent adherence to this session schedule occasionally arise. This current retrospective study explores whether deviations from this “optimal” TMS treatment schedule impact final depression clinical outcomes in a naturalistic treatment setting.

Presented by Fatih Kokdere, MD

Dr. Kokdere is currently a psychiatry resident at MercyOne Medical Center in Des Moines, Iowa. He has worked as a research scholar at Butler Hospital TMS Clinic and Neuromodulation Research Facility under the supervision of Dr. Linda Carpenter after completing his medical education in Istanbul, Turkey.

Systematic Review and Meta-Analysis Comparing iTBS vs. TMS vs. Sham in Randomized Controlled Trials

Intermittent theta-burst stimulation (iTBS) is being used more frequently for the treatment of major depressive disorder. It has advantages, including a shorter duration of therapy. The objective was to evaluate the outcomes (response and safety/adverse events) of intermittent theta-burst stimulation (iTBS) to repetitive transcranial magnetic stimulation (rTMS) and to sham (iTBS v. sham) when used in patients with major depressive disorder (MDD) in randomized controlled trials (RCTs). The Cochrane methodology was used to evaluate the effect of iTBS in MDD. Results demonstrated a statistically significant improvement in the response of iTBS vs. sham; no statistical difference in this outcome when iTBS was compared to rTMS and; no statistical difference in adverse events when compared to sham. iTBS should be considered as a treatment alternative to rTMS in MDD.

A video recording for Abstract #25 is unavailable. Click here to check out the PDF abstract or register to view the poster at the CTMSS 2020 Virtual Poster Session and reach out directly to the author.

Author: Jeffrey D. Voigt, MBA, MPH

Jeff Voigt is an expert in the field of evidence assessments and cost-effectiveness analysis having published over 30 papers on these subjects in various peer-reviewed journals. Jeff is also an Associate Editor of Cost Effectiveness and Resource Allocation. Jeff resides and works in northern New Jersey.

Evaluation of Cognitive Performance in Clinically Depressed Patients Using THINC-it® After rTMS Treatment

This naturalistic, clinical study evaluated the cognitive performance of 265 patients primarily diagnosed with MDD, using THINC-it® Cognitive Screener.  Patients completed five daily treatments for 7-8 weeks (approx.. 36 total treatments) over the right dorsolateral prefrontal cortex (dlPFC) at 1 Hz for 360 pulses followed by left dlPFC stimulation at 20 Hz for 1200 pulses.  57.36% of patients achieved remission (≥ 70% improvement on PHQ-9) and significant moderate effect was found after rTMS in overall performance on the Choice Reaction Time Identification Task (d = -.38, p < .001) and Trail Making Test-Part B (d = -.39, p < .001). Cognitive performance after TMS suggests patients’ executive function, working memory, processing speed, and attention may have improved.

Presented by Naima Monira, MS

Naima Monira is a Clinical Analyst at Salience TMS Neuro Solutions. She obtained her B.A. in Psychology at Baylor University and both, her Masters in Human Development & Early Childhood Disorders and Applied Cognition & Neuroscience from the University of Texas at Dallas. In the past, Naima worked as a research clinician at the Center for BrainHealth at the University of Texas at Dallas and as a curriculum consultant at Hanson Robokind.

A Multicenter, Randomized, Sham-Controlled Trial of Left Prefrontal, 10 Hz, Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression

The objective of this study was to examine the feasibility, safety, and efficacy of 10 Hz repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder in adolescents. Based on the largest study of adolescents to date, Left prefrontal 10 Hz rTMS monotherapy appears to be feasible, tolerable, and safe in adolescents with treatment-resistant depression. Future studies should focus on study designs to reduce placebo response rates, larger sample size, and dose-finding approaches for adolescents with depression.

Presented by Paul E. Croarkin, DO, MS

Dr. Croarkin’s research program focuses on adapting and innovating brain stimulation interventions in children and adolescents. This includes biomarker work to optimize diagnostic practices and the delivery of brain-based interventions such as transcranial magnetic stimulation.  A central theme focuses on the role of gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems in early-onset mood disorders with the goal of informing safer and more effective biologic treatments. Dr. Croarkin is a professor of psychiatry in the Mayo Clinic College of Medicine and the Director of the Mayo Clinic Depression Center.

Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT-TRD) Induces Rapid remission from Treatment-Resistant Depression in a Double-Blinded, Randomized, and Controlled Trial

Major depressive disorder (MDD) is the leading cause of disability worldwide and half of patients have treatment-resistant depression (TRD). Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for TRD but is limited by suboptimal efficacy and 6-week treatment duration. We addressed this by developing Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), which was associated with a ~90% remission rate after 5 days of treatment in an open-label study. Herein, we report the results of a sham-controlled, double-blinded trial of SAINT for TRD.

Presented by Angela Leah Phillips, PhD, LICSW

Angela currently has a dual postdoctoral role with the Stanford Brain Stimulation Lab, and the VA, Palo Alto, CA, USA. She obtained her BA from the University of North Carolina in Clinical Psychology, followed by her MSW and clinical licensure in Mental Health Practice, and PhD in Nursing Science, from the University of Washington. Angela has worked across inpatient and outpatient clinical psychiatry for over a decade with research interests focusing on neuromodulatory psychiatric and mental health interventions, including novel non-invasive brain stimulation methods, and combined psychotherapeutic interventions for complex neurological and neuropsychiatric disorders.